Company release
Nanoform Finland Plc
June 13, 2022
10:00 a.m. Finnish time / 09:00 a.m. Swedish time
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Mads Laustsen’s receipt of a share-based incentive:
Person subject to the notification requirement
Name: Laustsen, Mads
Position: Member of the Board/Deputy member
Issuer: Nanoform Finland plc
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20220610161814_10
Transaction date: 2022-06-10
Venue: XHEL
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 12181 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 12181 Volume weighted average price: 0.00 EUR
For further information, please contact:
Peter Hänninen
General Counsel
+358 50 353 040
For investor relations queries, please contact:
Henri von Haartman
Director of Investor Relations
+46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.